Nipro Corporation
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Analyst Recommendations 5 analysts
Updated 2026/10/01Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/10 | ¥7.11 | ¥23.48 | +230.1% |
| 2026/05/12 | ¥-16.01 | ¥-19.50 | -21.8% |
| 2026/02/09 | ¥21.09 | ¥66.09 | +213.3% |
| 2025/11/10 | ¥22.44 | ¥16.15 | -28.0% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
4.6M | +5.77% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.2M | +0.93% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.5M | +1.34% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.1M | +0.29% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
972.8K | 0.00% | |
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
913.9K | +1.19% |
Dividend History 1Years Growth
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥31 | +34.8% |
| 2025 | ¥23 | -14.8% |
| 2024 | ¥27 | +45.9% |
| 2023 | ¥19 | -28.8% |
| 2022 | ¥26 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥494,789M | ¥545,199M | ¥586,785M | ¥644,586M |
| Gross Profit | ¥149,269M | ¥163,449M | ¥171,320M | ¥190,883M |
| Operating Income | ¥23,883M | ¥17,729M | ¥22,335M | ¥26,598M |
| Pretax Income | ¥27,378M | ¥21,278M | ¥25,746M | ¥26,931M |
| Net Income | ¥13,455M | ¥4,574M | ¥11,109M | ¥5,113M |
| EPS | ¥77.42 | ¥24.85 | ¥24.85 | ¥27.78 |
| Operating Margin | 4.83% | 3.25% | 3.81% | 4.13% |
| Balance Sheet | ||||
| Total Assets | ¥930,321M | ¥1,027,399M | ¥1,109,821M | ¥1,170,564M |
| Total Equity | ¥185,238M | ¥206,317M | ¥232,664M | ¥252,445M |
| Total Liabilities | ¥745,083M | ¥821,082M | ¥877,157M | ¥918,119M |
| Cash | ¥95,342M | ¥89,678M | ¥99,667M | ¥106,668M |
| Interest-bearing Debt | ¥564,852M | ¥605,931M | ¥635,687M | ¥636,873M |
| Equity Ratio | 19.91% | 20.08% | 20.96% | 21.57% |
| D/E Ratio | 3.05 | 2.94 | 2.73 | 2.52 |
| Cash Flow | ||||
| Operating CF | ¥68,214M | ¥10,395M | ¥72,936M | ¥68,461M |
| Investing CF | -¥78,434M | -¥71,737M | -¥87,075M | -¥71,876M |
| Financing CF | ¥10,297M | ¥43,077M | ¥22,142M | ¥5,376M |
| Free CF | ¥68,214M | ¥10,395M | ¥72,936M | ¥68,461M |
| Efficiency | ||||
| ROE | 7.26% | 2.22% | 4.77% | 2.03% |
| ROA | 1.45% | 0.45% | 1.00% | 0.44% |
Latest IR Information
-
Notice regarding the results of conversion and redemption of the 2026 maturing euro-yen denominated convertible bonds with stock acquisition rights
Cumulative conversion amount of the convertible bonds with stock acquisition rights: 29,930 million yen (conversion rate 99.8%), conversion completed. Redemption amount of 70 million yen will be 100% redeemed on the redemption due date of September 25, 2026. Through conversion,...
Read more -
[Nipro] Q1 Consolidated Financial Results for the Period Ending March 2027｜First Quarter
For the first quarter of the fiscal year ending March 2027, the consolidated results show net sales of 159,220 million yen, operating income of 7,212 million yen, ordinary income of 7,385 million yen, and net income attributable to owners of...
Read more -
【Nipro Group】Projected Capital Gains from Sale of Investment Securities ｜ July 2026
Nipro Group announced that it plans to sell the shares of Atnaorp Corporation, a target investment, and expects to recognize approximately 3,900 million yen as a special gain in the fiscal year ending March 2027.
Read more -
[Nipro] Subsidiary Sale and Business Restructuring | June 2026
Nipro resolved at its Board of Directors meeting on June 26, 2026, to transfer shares of the subsidiaries Gentuity and the equity-method affiliate Spryte, implementing a business restructuring. There will be no impact on consolidated performance, with transfer amounts approximately...
Read more -
Notice of Partial Amendment to Articles of Incorporation | June 26, 2026
Nipro Corporation announced that it plans to seek shareholder approval at the General Meeting of Shareholders on June 26, 2026, for a partial amendment to its Articles of Incorporation aimed at enhancing management flexibility.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,996
Rating Score: 2.40 (Based on 5 analysts)
※1=Strong Buy, 5=Strong Sell
Japan's Nipro Corp establishes Asia Pacific regional headquarters in Singapore - BioSpectrum Asia ↗
Company Information
About
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses worldwide. The company offers renal products; interventional products, such as cardiovascular products, endovascular products, and accessories; and hospital products, including hypodermic needles, syringes, IV sets and catheters, 3-way stopcocks, infusion sets, balloon infusers, etc. It also provides cardiopulmonary products comprising oxygenators, cardioplegia heat exchangers, perfusion tubing sets, arterial filters, hemoconcentrators, and venous and arterial cannulae; and enzymes, as well as contract development and manufacturing services. In addition, the company offers pharmaceutical combination products consisting of dual chamber bags, pre-filled syringes, and half-type kits; and integrated services, such as development, manufacturing, inspection, and packaging. Further, it provides glass containers, rubber stoppers, glass tubes, and other supplies for medical use; supplies for other industries; and drug administration systems, as well as autologous bone-marrow mesenchymal stem cells, culture products, and cell preservation products. The company was founded in 1947 and is headquartered in Settsu, Japan.
